For Edwards Lifesciences Corporation [EW], Wells Fargo sees a drop to $230. What next?

Edwards Lifesciences Corporation [NYSE: EW] price plunged by -2.00 percent to reach at -$1.75. The company report on July 23, 2020 that Edwards Lifesciences Reports Second Quarter Results.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2020.

Second Quarter Highlights and Outlook .

A sum of 4136372 shares traded at recent session while its average daily volume was at 2.79M shares. Edwards Lifesciences Corporation shares reached a high of $87.595 and dropped to a low of $84.945 until finishing in the latest session at $85.69.

The one-year EW stock forecast points to a potential upside of 1.78. The average equity rating for EW stock is currently 2.00, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Edwards Lifesciences Corporation [EW]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EW shares is $87.24 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EW stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Wells Fargo have made an estimate for Edwards Lifesciences Corporation shares, keeping their opinion on the stock as Equal Weight, with their previous recommendation back on April 28, 2020. The new note on the price target was released on April 17, 2020, representing the official price target for Edwards Lifesciences Corporation stock. Previously, the target price had yet another raise to $252, while Citigroup analysts kept a Buy rating on EW stock.

The Average True Range (ATR) for Edwards Lifesciences Corporation is set at 1.82, with the Price to Sales ratio for EW stock in the period of the last 12 months amounting to 12.24. The Price to Book ratio for the last quarter was 13.84, with the Price to Cash per share for the same quarter was set at 1.89. Price to Free Cash Flow for EW in the course of the last twelve months was 56.45 with Quick ratio for the last quarter at 2.20.

EW Stock Performance Analysis:

Edwards Lifesciences Corporation [EW] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.38. With this latest performance, EW shares gained by 9.69% in over the last four-week period, additionally plugging by 24.88% over the last 6 months – not to mention a rise of 14.26% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EW stock in for the last two-week period is set at 71.69, with the RSI for the last a single of trading hit 71.16, and the three-weeks RSI is set at 67.50 for Edwards Lifesciences Corporation [EW]. The present Moving Average for the last 50 days of trading for this stock 76.19, while it was recorded at 85.84 for the last single week of trading, and 73.95 for the last 200 days.

Insight into Edwards Lifesciences Corporation Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Edwards Lifesciences Corporation [EW] shares currently have an operating margin of +27.55 and a Gross Margin at +73.43. Edwards Lifesciences Corporation’s Net Margin is presently recorded at +24.08.

Return on Total Capital for EW is now 27.98, given the latest momentum, and Return on Invested Capital for the company is 24.53. Return on Equity for this stock inclined to 28.73, with Return on Assets sitting at 17.73. When it comes to the capital structure of this company, Edwards Lifesciences Corporation [EW] has a Total Debt to Total Equity ratio set at 16.36. Additionally, EW Total Debt to Total Capital is recorded at 14.06, with Total Debt to Total Assets ending up at 10.46. Long-Term Debt to Equity for the company is recorded at 15.75, with the Long-Term Debt to Total Capital now at 13.53.

Reflecting on the efficiency of the workforce at the company, Edwards Lifesciences Corporation [EW] managed to generate an average of $75,317 per employee. Receivables Turnover for the company is 7.65 with a Total Asset Turnover recorded at a value of 0.74.Edwards Lifesciences Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 3.10.

EW Stock EPS

With the latest financial reports released by the company, Edwards Lifesciences Corporation posted 0.47/share EPS, while the average EPS was predicted by analysts to be reported at 0.41/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 14.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EW. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Edwards Lifesciences Corporation go to 12.17%.

Edwards Lifesciences Corporation [EW] Insider Position Details

There are presently around $43,850 million, or 86.30% of EW stock, in the hands of institutional investors. The top three institutional holders of EW stocks are: BLACKROCK INC. with ownership of 59,443,975, which is approximately 6.189% of the company’s market cap and around 0.10% of the total institutional ownership; VANGUARD GROUP INC, holding 49,428,510 shares of the stock with an approximate value of $4.24 billion in EW stocks shares; and STATE STREET CORP, currently with $2.33 billion in EW stock with ownership of nearly 0.931% of the company’s market capitalization.

Positions in Edwards Lifesciences Corporation stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 493 institutional holders increased their position in Edwards Lifesciences Corporation [NYSE:EW] by around 30,221,846 shares. Additionally, 475 investors decreased positions by around 34,525,566 shares, while 174 investors held positions by with 446,979,981 shares. The mentioned changes placed institutional holdings at 511,727,393 shares, according to the latest SEC report filing. EW stock had 116 new institutional investments in for a total of 6,204,013 shares, while 99 institutional investors sold positions of 5,103,990 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *



Download Free eBook For


100% free. stop anytime no spam



Download Free eBook For


100% free. stop anytime no spam